# Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

> **NCT05544968** · PHASE1 · RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 42 (estimated)

## Conditions studied

- Hodgkin Disease
- CD30-Positive Diffuse Large B-Cell Lymphoma
- CD30+ Anaplastic Large Cell Lymphoma
- CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma
- CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma
- Leukemia
- Lymphoma

## Interventions

- **DRUG:** anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT05544968
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-04
- **Primary completion:** 2028-01
- **Final completion:** 2029-07
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05544968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05544968, "Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05544968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*